We are live on
!
Find out more
Cardiff Oncology
CRDF
CRDF
117 hedge funds and large institutions have $122M invested in Cardiff Oncology in 2024 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 40 increasing their positions, 16 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
1,133% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 3
258% more capital invested
Capital invested by funds: $34.1M → $122M (+$87.8M)
253% more call options, than puts
Call options by funds: $4.64M | Put options by funds: $1.32M
150% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 16
41% more funds holding
Funds holding: 83 → 117 (+34)
14.82% more ownership
Funds ownership: 27.41% → 42.23% (+15%)
Holders
117
Holders Change
+34
Holders Change %
+40.96%
% of All Funds
1.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
37
Increased
40
Reduced
16
Closed
3
Calls
$4.64M
Puts
$1.32M
Net Calls
+$3.32M
Net Calls Change
+$1.54M
Top Buyers
| 1 |
CC
Commodore Capital
New York
|
+$16.8M |
| 2 |
O
OrbiMed
New York
|
+$4.81M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.04M |
| 4 |
LCM
Laurion Capital Management
New York
|
+$1.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.59M |
Top Sellers
| 1 |
Two Sigma Advisers
New York
|
-$989K |
| 2 |
BC
BIT Capital
Berlin,
Germany
|
-$676K |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$635K |
| 4 |
Renaissance Technologies
New York
|
-$373K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$251K |
